Pandemic (H1N1) 2009 virus infection: Persistent viral shedding after Oseltamivir treatment - 18/09/11


Summary |
Objectives |
To study pandemic (H1N1) 2009 virological outcomes after Oseltamivir treatment in confirmed cases of pandemic (H1N1) 2009 virus infections. A hospital-based cohort study was conducted in south Thailand, between June and September 2009.
Methods |
Throat/swab specimens were tested by real-time reverse transcriptase polymerase chain reaction (rRT-PCR) for pandemic (H1N1) 2009. All 357 confirmed cases (122 inpatients, 235 outpatients), whose received a 5-day Oseltamivir treatment. Post-treatment virological follow-up was performed in 91 eligible cases. The NA gene was screened for the H275Y mutation responsible for Oseltamivir resistance.
Results |
Thirty-three of 91 patients (36%) had underlying diseases. The duration from the onset of illness to the detection of virus ranged 1–14 days (median 3 days). The rRT-PCR was positive on day 5 of treatment in 24 of 91 patients (26%). Patients with underlying diseases had a higher proportion of post-treatment positive test than those without underlying diseases (15/33 vs 9/58). The rRT-PCR-confirmed viruses detected in all 125 throat swab specimens did not show evidence suggesting Oseltamivir resistance.
Conclusions |
Prolonged presence of pandemic (H1N1) 2009 detected by rRT-PCR was found. An extended course of antiviral treatment should be considered in patients with underlying diseases and severe clinical symptoms.
Le texte complet de cet article est disponible en PDF.Keywords : Pandemic (H1N1) 2009, Influenza A, Viral shedding, Oseltamivir, Treatment
Plan
Vol 63 - N° 4
P. 295-299 - octobre 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?